HRP20030015A2 - Indole derivatives useful for the treatment of cns disorders - Google Patents
Indole derivatives useful for the treatment of cns disorders Download PDFInfo
- Publication number
- HRP20030015A2 HRP20030015A2 HR20030015A HRP20030015A HRP20030015A2 HR P20030015 A2 HRP20030015 A2 HR P20030015A2 HR 20030015 A HR20030015 A HR 20030015A HR P20030015 A HRP20030015 A HR P20030015A HR P20030015 A2 HRP20030015 A2 HR P20030015A2
- Authority
- HR
- Croatia
- Prior art keywords
- indole
- ethyl
- piperidin
- chloro
- methylphenyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 24
- 150000002475 indoles Chemical class 0.000 title claims description 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- -1 cyano, nitro, amino, hydroxy Chemical group 0.000 claims description 121
- 150000001875 compounds Chemical class 0.000 claims description 92
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 14
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 13
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 12
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 230000036506 anxiety Effects 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 230000016571 aggressive behavior Effects 0.000 claims description 4
- 239000000164 antipsychotic agent Substances 0.000 claims description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000007958 sleep Effects 0.000 claims description 4
- COKJNEXXCRXHKU-UHFFFAOYSA-N 1-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-(4-fluorophenyl)urea Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)NC1=CC=C(F)C=C1 COKJNEXXCRXHKU-UHFFFAOYSA-N 0.000 claims description 3
- SZCVKMOVEPYVAY-UHFFFAOYSA-N 3-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-1-methyl-1-phenylurea Chemical compound C=1C=C(C)C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)=CC=1NC(=O)N(C)C1=CC=CC=C1 SZCVKMOVEPYVAY-UHFFFAOYSA-N 0.000 claims description 3
- OZMNONYSCNSFPO-UHFFFAOYSA-N 3-cyclohexyl-n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]propanamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)CCC1CCCCC1 OZMNONYSCNSFPO-UHFFFAOYSA-N 0.000 claims description 3
- DSKIXYWEEZMPKP-UHFFFAOYSA-N 4-chloro-n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]benzamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 DSKIXYWEEZMPKP-UHFFFAOYSA-N 0.000 claims description 3
- UPWHNYKFYLPTLY-UHFFFAOYSA-N 4-fluoro-n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]benzamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=C(F)C=C1 UPWHNYKFYLPTLY-UHFFFAOYSA-N 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- SYBVOKCVTYSRPG-UHFFFAOYSA-N n-[3-[2-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(CCN3CCC(CC3)C=3C4=CC(Cl)=CC=C4NC=3)C(C)=CC=2)=C1 SYBVOKCVTYSRPG-UHFFFAOYSA-N 0.000 claims description 3
- XDPFARVEOFULEU-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 XDPFARVEOFULEU-UHFFFAOYSA-N 0.000 claims description 3
- NIFCQXBHZRSABD-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(CCN3CCC(CC3)C=3C4=CC(F)=CC=C4NC=3)C(C)=CC=2)=C1 NIFCQXBHZRSABD-UHFFFAOYSA-N 0.000 claims description 3
- PHNBIPAXSGYUAL-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-phenylpropanamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)CCC1=CC=CC=C1 PHNBIPAXSGYUAL-UHFFFAOYSA-N 0.000 claims description 3
- NUTRIFZDVOBUDS-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 NUTRIFZDVOBUDS-UHFFFAOYSA-N 0.000 claims description 3
- PXWRAGRXMNGNBJ-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclopropanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1CC1 PXWRAGRXMNGNBJ-UHFFFAOYSA-N 0.000 claims description 3
- YFLQNIXJLUAWHP-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]morpholine-4-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)N1CCOCC1 YFLQNIXJLUAWHP-UHFFFAOYSA-N 0.000 claims description 3
- HIMBSTFPSOTMBD-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 HIMBSTFPSOTMBD-UHFFFAOYSA-N 0.000 claims description 3
- ROYKPHBDQQUOPT-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)=C1 ROYKPHBDQQUOPT-UHFFFAOYSA-N 0.000 claims description 3
- GHKVCRWGSMPFBT-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]acetamide Chemical group CC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)=C1 GHKVCRWGSMPFBT-UHFFFAOYSA-N 0.000 claims description 3
- BJQIJWIVRSICQY-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclopentanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)C(C)=CC=C1NC(=O)C1CCCC1 BJQIJWIVRSICQY-UHFFFAOYSA-N 0.000 claims description 3
- GDWYHPJDBGGMAY-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 GDWYHPJDBGGMAY-UHFFFAOYSA-N 0.000 claims description 3
- BWBNZVJTOUWTRO-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiophene-2-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CS1 BWBNZVJTOUWTRO-UHFFFAOYSA-N 0.000 claims description 3
- XHNCUDFWPYXDNO-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-phenylpropanamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)CCC1=CC=CC=C1 XHNCUDFWPYXDNO-UHFFFAOYSA-N 0.000 claims description 3
- KFKUIMDCNNLHTM-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-fluorobenzamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=C(F)C=C1 KFKUIMDCNNLHTM-UHFFFAOYSA-N 0.000 claims description 3
- GDDHTDLBSUZWCA-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 GDDHTDLBSUZWCA-UHFFFAOYSA-N 0.000 claims description 3
- FMOBAHNKNCLUHS-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]benzamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CC=C1 FMOBAHNKNCLUHS-UHFFFAOYSA-N 0.000 claims description 3
- ICOKBOHVIJCZKC-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclopropanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1CC1 ICOKBOHVIJCZKC-UHFFFAOYSA-N 0.000 claims description 3
- NNRXNDWFUPQDHU-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]hexanamide Chemical compound CCCCCC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 NNRXNDWFUPQDHU-UHFFFAOYSA-N 0.000 claims description 3
- YIJBZDYVCNJSES-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 YIJBZDYVCNJSES-UHFFFAOYSA-N 0.000 claims description 3
- VKOBFZFQQXPWBP-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]pyridine-4-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=NC=C1 VKOBFZFQQXPWBP-UHFFFAOYSA-N 0.000 claims description 3
- WJQQWWVNJCNWMS-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiophene-2-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CS1 WJQQWWVNJCNWMS-UHFFFAOYSA-N 0.000 claims description 3
- PLQMWLUVQABXSI-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiophene-3-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C=1C=CSC=1 PLQMWLUVQABXSI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000003441 thioacyl group Chemical group 0.000 claims description 3
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- CSRGGHAQRBPQBW-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C(CCN2CC=C(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 CSRGGHAQRBPQBW-UHFFFAOYSA-N 0.000 claims description 2
- SRAQFFXJBJEVGN-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CC=C(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 SRAQFFXJBJEVGN-UHFFFAOYSA-N 0.000 claims description 2
- JIRPRUOEKMRRCC-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 JIRPRUOEKMRRCC-UHFFFAOYSA-N 0.000 claims description 2
- SIJAQKZIQFOKIC-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclobutanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1CCC1 SIJAQKZIQFOKIC-UHFFFAOYSA-N 0.000 claims description 2
- XQICOXCELYJLLR-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(CCN3CCC(CC3)C=3C4=CC=C(Cl)C=C4NC=3)C(C)=CC=2)=C1 XQICOXCELYJLLR-UHFFFAOYSA-N 0.000 claims description 2
- KJWRXPGADNQRCA-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclopropanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)C(C)=CC=C1NC(=O)C1CC1 KJWRXPGADNQRCA-UHFFFAOYSA-N 0.000 claims description 2
- KIXJKVGKALVEBC-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C(CCN2CC=C(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 KIXJKVGKALVEBC-UHFFFAOYSA-N 0.000 claims description 2
- HCHMGLZVWPQNSZ-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]pyridine-3-carboxamide Chemical compound C1=C(CCN2CC=C(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 HCHMGLZVWPQNSZ-UHFFFAOYSA-N 0.000 claims description 2
- IULCHZDFEFRUFG-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 IULCHZDFEFRUFG-UHFFFAOYSA-N 0.000 claims description 2
- SPOFUJQNHLVFOS-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)=C1 SPOFUJQNHLVFOS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 5
- CTWLIHIEDTYNRM-UHFFFAOYSA-N 4-fluoro-n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylphenyl]benzamide Chemical compound C1=C(CCN2CC=C(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=C(F)C=C1 CTWLIHIEDTYNRM-UHFFFAOYSA-N 0.000 claims 1
- MKEMFDINUGGRIP-UHFFFAOYSA-N n-[3-[2-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiophene-2-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(Cl)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CS1 MKEMFDINUGGRIP-UHFFFAOYSA-N 0.000 claims 1
- HKHYNBPXKNILOH-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2,2-dimethylpropanamide Chemical compound CC1=CC=C(NC(=O)C(C)(C)C)C=C1CCN1CCC(C=2C3=CC(F)=CC=C3NC=2)CC1 HKHYNBPXKNILOH-UHFFFAOYSA-N 0.000 claims 1
- YWXFDVJNZFOOMK-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]hexanamide Chemical compound CCCCCC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)=C1 YWXFDVJNZFOOMK-UHFFFAOYSA-N 0.000 claims 1
- HNCOPUVXUWJJQQ-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)=C1 HNCOPUVXUWJJQQ-UHFFFAOYSA-N 0.000 claims 1
- GQVIKVMHMCRODW-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiadiazole-5-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1=CN=NS1 GQVIKVMHMCRODW-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 229920005989 resin Polymers 0.000 description 22
- 239000011347 resin Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 14
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- LCKMHUXHKGYADQ-UHFFFAOYSA-N 3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylaniline Chemical compound CC1=CC=C(N)C=C1CCN1CCC(C=2C3=CC=CC(Cl)=C3NC=2)CC1 LCKMHUXHKGYADQ-UHFFFAOYSA-N 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000012452 mother liquor Substances 0.000 description 8
- 239000004793 Polystyrene Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910052721 tungsten Inorganic materials 0.000 description 6
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 101150049660 DRD2 gene Proteins 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000010933 acylation Effects 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000000561 anti-psychotic effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- JCSRJKWRJVUXSQ-UHFFFAOYSA-N 2-(2-methyl-5-nitrophenyl)acetic acid Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CC(O)=O JCSRJKWRJVUXSQ-UHFFFAOYSA-N 0.000 description 4
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 4
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 4
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 4
- 101150104779 HTR2A gene Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000002152 alkylating effect Effects 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000006396 nitration reaction Methods 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- VHHJXJSFEWEBPU-UHFFFAOYSA-N 2-(2-methyl-5-nitrophenyl)ethyl methanesulfonate Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CCOS(C)(=O)=O VHHJXJSFEWEBPU-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 3
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 2
- XMEOECCRILOHHP-UHFFFAOYSA-N 1-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-2-(2-methyl-5-nitrophenyl)ethanone Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CC(=O)N1CCC(C=2C3=CC=CC(Cl)=C3NC=2)CC1 XMEOECCRILOHHP-UHFFFAOYSA-N 0.000 description 2
- HKKLOIBMMSAEQY-UHFFFAOYSA-N 2-(2-bromoethyl)-1-methyl-4-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CCBr HKKLOIBMMSAEQY-UHFFFAOYSA-N 0.000 description 2
- UWSNLCKYQFYFEX-UHFFFAOYSA-N 2-(5-amino-2-methylphenyl)-1-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethanone Chemical compound CC1=CC=C(N)C=C1CC(=O)N1CCC(C=2C3=CC=CC(Cl)=C3NC=2)CC1 UWSNLCKYQFYFEX-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 2
- SCOQFHREQHSMFZ-UHFFFAOYSA-N 3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylaniline Chemical compound CC1=CC=C(N)C=C1CCN1CCC(C=2C3=CC(F)=CC=C3NC=2)CC1 SCOQFHREQHSMFZ-UHFFFAOYSA-N 0.000 description 2
- KUVDQLUBWRHNEP-UHFFFAOYSA-N 3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylaniline Chemical compound CC1=CC=C(N)C=C1CCN1CCC(C=2C3=CC=C(Cl)C=C3NC=2)CC1 KUVDQLUBWRHNEP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 2
- 108091005479 5-HT2 receptors Proteins 0.000 description 2
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 2
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 2
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 2
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- YSJJYGWMTGJNGH-UHFFFAOYSA-N carbon dioxide;ethane-1,2-diol Chemical compound O=C=O.OCCO YSJJYGWMTGJNGH-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960003368 croscarmellose sodium type a Drugs 0.000 description 2
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- LIUTZUVIOULSTE-UHFFFAOYSA-N n-[3-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]thiophene-2-carboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC(F)=CC=C3NC=2)C(C)=CC=C1NC(=O)C1=CC=CS1 LIUTZUVIOULSTE-UHFFFAOYSA-N 0.000 description 2
- FUXPECATVNUNGX-UHFFFAOYSA-N n-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=C(C)C(CCN2CCC(CC2)C=2C3=CC=C(Cl)C=C3NC=2)=C1 FUXPECATVNUNGX-UHFFFAOYSA-N 0.000 description 2
- GAJNABYGFQNROT-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)CC1=CC=C(F)C=C1 GAJNABYGFQNROT-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006636 (C3-C8) cycloalkylcarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LWKRBACLFMUOFV-UHFFFAOYSA-N 1-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]-2-(2-methyl-5-nitrophenyl)ethanone Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CC(=O)N1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 LWKRBACLFMUOFV-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- JGQPSDIWMGNAPE-UHFFFAOYSA-N 2,1-benzothiazole Chemical compound C1=CC=CC2=CSN=C21 JGQPSDIWMGNAPE-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- RZWGTXHSYZGXKF-UHFFFAOYSA-N 2-(2-methylphenyl)acetic acid Chemical compound CC1=CC=CC=C1CC(O)=O RZWGTXHSYZGXKF-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- KHMNCHDUSFCTGK-UHFFFAOYSA-N 2-aminophenylacetic acid Chemical compound NC1=CC=CC=C1CC(O)=O KHMNCHDUSFCTGK-UHFFFAOYSA-N 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- LWIOFILTAJJDLA-UHFFFAOYSA-N 2-methyl-3-nitrophenylacetic acid Chemical compound CC1=C(CC(O)=O)C=CC=C1[N+]([O-])=O LWIOFILTAJJDLA-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- CIRSPTXGPFAXRE-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C1NCCC(C=2C3=CC=CC=C3NC=2)=C1 CIRSPTXGPFAXRE-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WUJJRGYZMYBKHQ-UHFFFAOYSA-N 3-[2-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylaniline Chemical compound CC1=CC=C(N)C=C1CCN1CCC(C=2C3=CC(Cl)=CC=C3NC=2)CC1 WUJJRGYZMYBKHQ-UHFFFAOYSA-N 0.000 description 1
- XWLFQEOBCHQZSO-UHFFFAOYSA-N 3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-4-methylaniline Chemical compound CC1=CC=C(N)C=C1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 XWLFQEOBCHQZSO-UHFFFAOYSA-N 0.000 description 1
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical compound C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- IYDNBSITMDSZOF-UHFFFAOYSA-N 5-fluoro-3-[1-[2-(2-methyl-5-nitrophenyl)ethyl]piperidin-4-yl]-1h-indole Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CCN1CCC(C=2C3=CC(F)=CC=C3NC=2)CC1 IYDNBSITMDSZOF-UHFFFAOYSA-N 0.000 description 1
- VQFAITGIMWXQQK-UHFFFAOYSA-N 5-fluoro-3-piperidin-4-yl-1h-indole Chemical compound C12=CC(F)=CC=C2NC=C1C1CCNCC1 VQFAITGIMWXQQK-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DQGWEDRPBNHZDE-UHFFFAOYSA-N 6-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C=1NC2=CC(Cl)=CC=C2C=1C1=CCNCC1 DQGWEDRPBNHZDE-UHFFFAOYSA-N 0.000 description 1
- CYQAPXIAEFXKPZ-UHFFFAOYSA-N 7-chloro-3-piperidin-4-yl-1h-indole Chemical compound C=1NC=2C(Cl)=CC=CC=2C=1C1CCNCC1 CYQAPXIAEFXKPZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229940124243 Dopamine D4 receptor antagonist Drugs 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- 101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229910000086 alane Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002539 anti-aggressive effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- OFJLSOXXIMLDDL-UHFFFAOYSA-N ethyl (4-nitrophenyl) carbonate Chemical compound CCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 OFJLSOXXIMLDDL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- HSJDRNJAYXUCGQ-UHFFFAOYSA-N n-[3-[2-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-4-methylphenyl]cyclobutanecarboxamide Chemical compound C1=C(CCN2CCC(CC2)C=2C3=CC=CC(Cl)=C3NC=2)C(C)=CC=C1NC(=O)C1CCC1 HSJDRNJAYXUCGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- WUHLVXDDBHWHLQ-UHFFFAOYSA-N pentazole Chemical group N=1N=NNN=1 WUHLVXDDBHWHLQ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 108010092215 spiroperidol receptor Proteins 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- QYTJFOBUAJLXAR-UHFFFAOYSA-N tert-butyl 4-(5-fluoro-1h-indol-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CNC2=CC=C(F)C=C12 QYTJFOBUAJLXAR-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- ZPHGMBGIFODUMF-UHFFFAOYSA-N thiophen-2-ylmethanol Chemical compound OCC1=CC=CS1 ZPHGMBGIFODUMF-UHFFFAOYSA-N 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- QTWBEVAYYDZLQL-UHFFFAOYSA-N thiophene-3-carbonyl chloride Chemical compound ClC(=O)C=1C=CSC=1 QTWBEVAYYDZLQL-UHFFFAOYSA-N 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Description
Područje izuma
Ovaj se izum odnosi na novu klasu derivata indola koji imaju afinitet prema receptoru dopamina D4. Ti spojevi imaju antagonističko djelovanje na receptor dopamina D4 i zato su korisni za liječenje stanovitih psihijatrijskih i neuroloških poremećaja, posebno psihoza. Neki od spojeva imaju i afinitet prema 5-HT2A i/ili 5-HT2C receptor, a neki od spojeva su inhibitori ponovnog preuzimanja serotonina.
Prethodno stanje struke
AT 332401 opisuje spojeve opće formule
[image]
u kojoj je R vodik ili alkil, R1 i R2 su vodik ili alkil, p je 2 ili3, a X1 je vodik, fluor, krom ili brom. Za te se spojeve tvrdi da su korisni kao neuroleptici. Taj patent ne sadrži nikakve podatke o pokusima.
WO 95/11680 odnosi na široku klasu spojeva koji imaju antipsihotičko djelovanje. Jedna skupina od tih spojeva su spojevi koji imaju formulu
[image]
u kojoj X1 znači O, S, NH ili NR2, Alk je alkilen, W1 je CH2, O, S ili NH, a R je vodik, alkil, alkoksi, hidroksi, karboksil, halogen, amino, alkilamino, dialkilamino, nitro, alkitio, trifluorometoksi, cijano, acilamino, trifluoroacetil, aminokarbonil, monoalkilaminokarbonil, dialkilaminokarbonil itd. Primjena ne objašnjava nikakav mehanizam djelovanja, ali se kaže da spojevi imaju smanjenu tendenciju izazivanja ekstrapiramidalnih nuspojava.
Receptori dopamina D4 spadaju u podvrstu receptora dopamina D2, koja se smatra odgovornom za antipsihotičko djelovanje neuroleptika. Poznato je da do nuspojava kod neuroleptičkih lijekova, koje primarno pokazuju svoje djelovanje kroz antagonizam D2 receptora, dolazi zbog antagonizma D2 receptora u strijatalnim područjima mozga. Međutim, receptori dopamina D4 primarno su smješteni u područjima mozga izvan striatuma, što ukazuje na to da selektivni antagonisti receptora dopamina D4 neće uzrokovati ekstrapiramidalne nuspojave. To je ilustrirano antipsihotikom clozapinom, koji pokazuje veći afinitet prema D4 nego D2 receptorima i kod kojeg nema ekstrapiramidalnih nuspojava (Van Tol i sur. Nature 1991., 350, 610; Hadley Medicinal Research Reviews 1996., 16, 507-526 i Sanner Exp. Opin. Ther. Patents 1998., 8, 383-393).
Pokazalo se da niz D4 liganda, za koje se tvrdilo da su selektivni antagonisti D4 receptora (L-745,879 i U-101958), posjeduje antipsihotičko djelovanje (Mansbach i sur. Phychopharmacology 1998., 135, 194-200). Međutim, nedavno je objavljeno da su se ti spojevi u različitim in vitro pokusima djelotvornosti pokazali djelomičnim agonistima D4 receptora (Gazi i sur. Br. J. Pharmacol. 1998., 124, 889-896 i Gazi i sur. Br. J. Pharmacol. 1999., 128, 613-620). Nadalje se pokazalo da je djelotvorni antipsihotik clozapine tihi D4 antagonist (Gazi i sur. Br. J. Pharmacol. 1999., 128, 613-620).
Prema tome, D4 ligandi koji su djelomični agonisti ili antagonisti D4 receptora mogu imati blagotvorno djelovanje protiv psihoza.
Antagonisti dopamina D4 mogu biti korisni i za liječenje kognitivnih deficita (Jentsch i sur. Psychopharmacology 1999., 142, 78-84).
Nadalje, objavljen je dokaz o vezi između "primarno nepažljivog" podtipa poremećaja nedostatka koncentracije i hiperaktivnosti (ADHD) i poliformizma u vidu tandemskog podvostručenja u genu koji šifrira receptor dopamina D4 (McCracken i sur. Mol Phychiatry 2000., 5, 531-536). To jasno pokazuje na postojanje veze između receptora dopamina D4 i ADHD, a ligandi koji djeluju na taj receptor mogu biti korisni za liječenje upravo tog poremećaja.
Poznata su različita djelovanja s obzirom na spojeve koji su ligandi kod raznih podtipova receptora serotonina. Što se tiče 5-HT2A receptora, o kojem se ranije govorilo kao o 5-HT2 receptoru, objavljeni su njegovi sljedeći učinci:
Antidepresivno djelovanje i poboljšanje kakvoće spavanja (Meert i sur. Drug Dev. Res. 1989., 18, 119), smanjenje negativnih simptoma shizofrenije i ekstrapiramidalnih nuspojava izazvanih liječenjem klasičnim neurolepticima kod bolesnika od shizofrenije (Gelders British J. Psychiatry 1989., 155 (dod. 5), 33). Nadalje, selektivni 5-HT2A antagonisti mogu djelovati u profilaksi i liječenju migrene (kratki izvještaj; "Migraine - Current trends in research and treatment"; PJB Publications Ltd., svibanj 1991.) i kod liječenja tjeskobe (Colpart i sur. Phychopharmacology 1985., 86, 303-305 i Perregaard i sur. Current Opinion in Therapeutic Patents 1993., 1, 101-128).
Neke kliničke studije uključuju 5-HT2 podtip receptora u agresivno ponašanje. Osim toga, neuroleptici koji su atipični serotonin-dopamin antagonisti imaju, uz svoja svojstva blokade dopamina, i antagonističko djelovanje 5-HT2 receptora, a opisano je da posjeduju antiagresivno ponašanje (Connor i sur. Opin. Ther. Patents 1998., 8(4), 350-351).
Nedavno su prikupljeni dokazi koji idu u prilog gledanju na selektrivne 5-HT2A antagoniste kao na lijekove koji su u stanju liječiti pozitivne simptome psihoze (Leysen i sur. Current Pharmacuetical Design 1997., 3, 367-390 i Carlsson Current Opinion in CPNS Investigational Drugs 2000., 2(1), 22-24).
Spojevi koji su inhibitori ponovne pohrane 5-HT poznati su antidepresivi.
U mikodijalitičkim pokusima i pokusima na životinjama nađeno je da 5-HT2C ligandi povećavaju učinak inhibitora ponovnog preuzimanja 5-HT, a spojevi koji imaju inhibirajući učinak na ponovno preuzimanje 5-HT kombiniran s afinitetom prema 5-HT2C receptoru mogu zato djelomično biti korisni za liječenje depresije i drugih poremećaja koji reagiraju na inhibitore ponovne pohrane serotonina (PCT prijava br. PCT/DK00/00671).
Prema tome, ligandi receptora dopamina D4 potencijalni su lijekovi za liječenje shizofrenije i drugih psihoza, a spojevi s kombiniranim djelovanjem na 5-HT prijenosnik mogu imati daljnji blagotvorni učinak na depresivne i negativne simptome kod bolesnika od shizofrenije. Spojevi s kombiniranim djelovanjem na receptor dopamina D4 i 5-HT2A receptor mogu imati bolji učinak na pozitivne i negativne simptome shizofrenije i djelovati na simptome depresije i tjeskobe.
Posebno se spojevi prema ovom izumu smatraju korisnima kod liječenja pozitivnih i negativnih simptoma shizofrenije bez izazivanja ekstrapiramidalnih nuspojava.
Kratki opis izuma
Predmet ovog izuma je predstaviti spojeve koji su djelomični agonisti ili antagonisti receptora dopamina D4 i takve spojeve s kombiniranim djelovanjem na receptor dopamina D4, 5-HT2A receptor, 5-HT2C i/ili 5-HT prijenosnik.
Prema tome, ovaj se izum odnosi na nove spojeve formule I
[image]
u kojoj je R1 vodik ili C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil ili C3-8-cikloalkil-C1-6-alkil, koji svi mogu biti jednom ili više puta supstituirani supstituentima odabranima iz halogena, cijano, nitro, amino, hidroksi, tiola, C1-6-alkoksi, C1-6-alkitio, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila ili je R1 aril, aril-C1-6-alkil, heteroaril, heteroaril-C1-6-alkil, pri čemu arilne i heteroarilne skupine mogu biti jednom ili više puta supstiturane supstituentima odabranima iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, triflurometila, trifluorometilsulfonila i C1-6-alkilsulfonila, ili R1 znači –NR'R'', pri čemu su R' i R'' neovisno odabrani iz vodika i C1-6-alkila, arila, aril-C1-6-alkila, heteroarila i heteroaril-C1-6-alkila, od kojih svi mogu jednom ili više puta biti supstituirani supstituentima odabranim iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila, ili je R1 zasićeni prsten s 5 do 6 članova koji sadrži jedan, dva ili tri hetero atoma odabranih iz O, S i skupinu N-R9, gdje je R9 vodik ili C1-6-alkil opcionalno supstituiran supstituentima odabranih iz halogena, cijano, nitro, amino, C1-6-alkoski, C1-6-alkitio, hidroksi, tiola, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila;
W je veza ili W znači O, S, CO, CS, SO ili SO2 skupinu;
n je 0-6, m je 0-6, a n+m je 0-6; pod uvjetom da kad W znači O ili S, n ≥ 2, a kad W znači CO, CS; SO ili SO2, n ≥ 1;
X je C, CH ili N, a točkasta crta koja počinje od X označava vezu kad X znači C i nepostojanje veze kad X znači N ili CH;
R2 je C1-6-alkil;
R3-R7 odabrani su iz vodika, halogena, cijano, nitro, amino, C1-6-alkila, C2-6-alkenila, C2-6-alkinila, C3-8-cikloalkila, C3-8-cikloalkil-C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila;
R8 je vodik, C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil, C3-8-cikloalkil-C1-6-alkil, aril, aril-C1-6-alkil, acil, tioacil, C1-6-alkilsulfonil, trifluorometilsulfonil ili arilsulfonil ili njihove farmaceutski prihvatljive kiselinske soli.
U posebnoj varijanti, ovaj se izum odnosi na spojeve u kojima je indol vezan na X preko položaja 3 indola.
U drugoj izvedbi ovaj se izum odnosi na spojeve u kojima je W veza. Posebno se ovaj izum odnosi na spojeve u kojima n + m znači 2.
U daljnjoj se verziji ovaj izum odnosi na spojeve u kojima R2 znači metilnu skupinu.
U još jednoj verziji ovaj se izum odnosi na spojeve u kojima je skupina –NH-CO-R1 vezana na fenilnu skupinu u položaju suprotnom od položaja R2 skupine.
Posebno se ovaj izum odnosi na spojeve u kojima R1 znači C1-6-alkil, C3-8-cikloalkil, C3-8-cikloalkil-C1-6-alkil, fenil, fenil-C1-6-alkil, furanil, tienil, piridil, pirolil, pirimidil, pri čemu fenilne skupine mogu jednom ili više puta biti supstituirane supstituentima odabranim iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila, ili R1 znači –NR'R'', gdje je jedan od R' i R'' odabran iz vodika, a drugi od R' i R'' je odabran iz C1-6-alkila, fenila i fenil-C1-6-alkila, pri čemu fenilne skupine mogu jednom ili više puta biti supstituirane supstituentima odabranim iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila, ili je R1 tetrahidropiranil, morfolino, tiomorfolino, piperidino, piperazino ili N-(hidroksi-C1-6-alkil)piperazino skupina.
U specifičnoj verziji ovaj se izum odnosi na spoj odabran iz
3-(1-{2-[5-(Acetilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-(Ciklobutilmetanoilamino)-2-metilfenil]etil}piperidin-4-1il)-5-fluoro-1H-indola;
3-(1-{2-[5-(Acetilamino)-2-metilfenil]etil}piperidin-4-1il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(tiofen-1-ilmetanoilamino)fenil]etil}piperidini-4-il)-5-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(3-metoksibenzoilamino)phenil]etil}piperidin-4-il)-5-kloro-1H-indola;
3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol;
3-(1-{2-[2-Metil-5-(tiofen-2ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(Izobutanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(pivaroilamino)fenil]etil}piperidin-4-il)-5-flruoro-1H-indola;
3-(1-{2-[5-(Heksanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-H-indola;
3-(1-{2-[5-(4-Fluorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(3-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol;
3-(1-{2-[2-Metil-5-(piridin-3-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(3-fenilpropanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(3-Metil-3-fenilureido)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(tiofen-2-ilmetanoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-(Izobutanoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-(3-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(piridin-3-ilmetanoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-[1-(2-{5-[2-(4-Metoksifenil)etanolamino]-2-metilfenil}etil)piperidin-4-il]-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-[1-(2-{5-[(Ciklopentilmetanoil)amino]-2-metilfenil}etil)piperidin-4-il]-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(morfolin-4-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-[1-(2-{5-[3-(4-Fluorofenil)ureido]-2-metilfenil}etil)piperidin-4-il]-5-fluoro-1H-indola;
3-(1-{2-[5-(Heksanoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(tetrahidrofuran-4-ilmetanoilemino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(4-Klorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(3-Cikloheksilpropanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-[1-(2-{5-[(3-Fenilpropanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{5-[(2-Feniletanoil)amino]-2.etilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidini-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-[1-(2-{5-[2-(4-Fluorofenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{5-[2-(4-Metoksifenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{5-[(Ciklobutilmetanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-(1-{2-[5-(benzoilamino)-2-Metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(4-Fluorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(4-Metoksibenzoilamino)-2-metilfenil]etilpiperidin-4-il)-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-4-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(tiofen-2-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(tiofen-3-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(1-[1,2,3]tioadiazol-5-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-{1-[2-(5-Acetilamino-2-metilfenil)-etil]-3,6-dihidro-2H-piridin-4-il}-5-fluoro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)-amino]fenil}-etil)-3,6-dihidro-2H-piridin-4-il]-5-fluoro-1H-indola;
3-[1-(2-{5-[(4-Fluorofenilmetanoil)-qmino]-2metilfenil}-etil)-3,6-dihidro-2H-piridin-4-il]-5-fluoro-1H-indola;
3-{1-[2-(5-Acetilamino-2-metilfenil)-etil]-3,6-dihidro-2H-piridin-4-il}-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)-amino]-fenil}-etil)-3,6-dihidro-2H-piridin-4-il]-7-kloro-1H-indola i
3-[1-(2-{5-[(4-Fluorofenilmetanoil)-amino]-2-metilfenil}-etil)-3,5-dihidro-2H-piridin-4-il]-7-kloro-1H indola i njihovih farmaceutski prihvatljivih soli.
Spojevi prema ovom izumu su djelomični agonisti ili antagonisti receptora dopamina D4. Mnogi spojevi imaju kombinirano djelovanje na receptore dopamina D4 te 5-HT2A receptor, 5-HT2C receptor i/ili inhibirajuće djelovanje na ponovno preuzimanje ponovnog preuzimanja 5-HT.
Prema tome, spojevi prema ovom izumu smatraju se korisnima u liječenju pozitivnih i negativnih simptoma shizofrenije, drugih psihoza, tjeskobe, poput opće tjeskobe, panike i opsesivno kompulzivnog poremećaja, depresije, agresije, nuspojava izazvanih konvencionalnim antipsihotičkim agensima, migrene, kognitivnim poremećajima, ADHD te za poboljšanje spavanja.
Posebno se spojevi prema ovom izumu smatraju korisnima u liječenju pozitivnih i negativnih simptoma shizofrenije bez izazivanja ekstrapiramidalnih nuspojava.
U drugom aspektu, ovaj izum predstavlja farmaceutsku smjesu koja sadrži bar jedan spoj formule I prema gornjoj definiciji ili njegovu farmaceutski prihvatljivu kiselinsku sol u terapeutski djelotvornoj količini i u kombinaciji s jednim ili više farmaceutski prihvatljivih nositelja ili razrjeđivača.
U daljnjem aspektu, ovaj izum predstavlja uporabu spoja formule I prema gornjoj definiciji ili njegove farmaceutski prihvatljive kiselinske soli za proizvodnju farmaceutskog pripravka za liječenje gore spomenutih poremećaja.
Detaljni opis izuma
Spojevi opće formule I mogu postojati kao njihovi optički izomeri i takvi su optički izomeri također obuhvaćeni ovim izumom.
Izraz C1-6-alkil odnosi se na razgranatu ili nerazgranatu alkilnu skupinu koja ima jedan do uključivo šest atoma ugljika, poput metila, etila, 1-propila, 1-butila, 2-butila, 2-metil-2-propila i 2-metil-1-propila.
Slično tome, C2-6-alkenil odnosno C2-6-alkinil označavaju skupine koje imaju dva do šest atoma ugljika, uključujući jednu dvostruku odnosno trostruku vezu, poput etenila, propenila, butenila, etinila, propinila i butinila.
Izrazi C1-6-alkoksi, C1-6-alkitio, C1-6-alkilsulfonil, C1-6-alkilamino, C1-6-alkilkarbonil i slično označavaju skupine u kojima je alkilna skupina C1-6-alkil prema gornjoj definiciji.
Izraz C3-8-cikloalkil označava monociklični ili biciklični karboprsten koji ima tri do osam atoma ugljika, poput ciklopropila, ciklopentila, cikloheksila itd.
Halogen znači fluor, krom, brom ili jod.
Ovdje korišteni izraz acil odnosi se na formil, C1-6-alkilkarbonil, arilkarbonil, aril-C1-6-alkilkarbonil, C3-8-cikloalkilkarbonil ili C3-8-cikloalkil-C1-6-alkil-karbonilnu skupinu, a izraz tioacil znači odgovarajuću acilnu skupinu u kojoj je karbonilna skupina zamijenjena tiokarbonilnom.
Izraz aril odnosi se na karbocikličnu aromatsku skupinu, poput fenila ili naftila, posebno fenila.
Izraz heteroaril odnosi se na peteročlane monociklične prstene poput 1H-tetrazolila, 3H-1,2,3-oksatiazolila, 3H-1,2,4-oksatiazolila, 3H-1,2,5-oksatiazo-lila, 1,3,2-oksatiazolila, 1,3,4-oksatiazolila, 1,4,2-oksatiazolila, 3H-1,2,4-diok-sazolila, 1,3,2-dioksazolila, 1,4,2-dioksazolila, 3H-1,2,3-ditiazolila, 3H-1,2,4-ditiazolila, 1,3,2-ditiazolila, 1,4,2-ditiazolila, 1,2,3-oksadiazolila, 1,2,4-oksa- diazolil, 1,2,5-oksadiazolila, 1,3,4-oksadiazolila, 1,2,3-tiadiazolila, 1,2,4-tia-diazolila, 1,2,5-tiadiazolila, 1,3,4-tiadiazolila, 1H-1,2,3-triazolila, 1H-1,2,4-triazolila, izoksazolila, oksazolila, izotiazolila, tiazolila, 1H-imidazolila, 1H-pirazolila, 1H-pirolila, furanila, tienila, 1H-pentazola, na šesteročlane mono-ciklične prstene poput 1,2,3-oksatiazinila, 1,2,4,-oksatiazinila, 1,2,5-oksa-tiazinila, 4H-1,3,5-oksatiazinila, 1,4,2-oksatiazinila, 1,4,3-oksatiazinila, 1,2,3-dioksazinila, 1,2,4-dioksazinila, 4H-1,3,2-dioksazinila, 4H-1,3,5-dioksazinila, 1,4,2-dioksazinila, 2H-1,5,2-dioksazinila, 1,2,3-ditiazinila, 1,2,4-diitiazinila, 4H-1,3,2-ditiazinila, 4H-1,3,5-ditiazinila, 1,4,2-ditiazinila, 2H-1,5,2-ditiazinila, 2H-1,2,3-oksadiazinila, 2H-1,2,4-oksadiazinila, 2H-1,2,5-oksadiazinila, 2H-1,2,6-oksadiazinila, 2H-1,3,4-oksadiazinila, 2H-1,3,5-oksadiazinila, 2H-1,2,3-tiadiazinila, 2H-1,2,4-tiadiazinila, 2H-1,2,5-tiadiazinila, 2H-1,2,6-tiadiazinila, 2H-1,3,4-tiadiazinila, 2H-1,3,5-tiadiazinila, 1,2,3-triazinila, 1,2,4-triazinila, 1,3,5-triazinila, 2H-1,2-oksazinila, 2H-1,3-oksazinila, 2H-1,4-oksazinila, 2H-1,2-tiazinila, 2H-1,3-tiazinila, 2H-1,4-tiazinila, pirazinila, piridazinila, pirimidila, piridila, 2H-piranila, 2H-tiinila ili na biciklične prstene poput 3H-1,2,3-benzok-satiazolila, 1,3,2-benzodioksazolila, 3H-1,2,3-benzodtiazolila, 1,3,2-benzodi-tiazolila, benzofuranazila, 1,2,3-benzoksadiazolila, 1,2,3-benzotiadiazolila, 2,1,3-benzotiadiazolila, 1H-benzotriazolila, 1,2-benzisoksiazolila, 2,1-benzis-oksazolila, benzoksazolila, 1,2-benzisotiazolila, 2,1-benzisotiazolila, benzo-tiazolila, 1H-benzimidazilola, 1H-indazolila, 3H-1,2-benzoksatiolila, 1,3-benzo-ksatiolila, 3H-2,1-benzoksatiolila, 3H-1,2-benzodioksolila, 1,3-benzodioksolila, 3H-1,2-benzoditiolila, 1,3-benzoditiolila, 1H-indolila, 2H-izoindolila, benzofu-ranila, izobenzofuranila, 1-benzotienila, 2-benzotienila, 1H-2,1-benzoksazini-la, 1H-2,3-benzoksazinila, 2H-1,2-benzoksazinila, 2H-1,3-benzoksazinila, 2H-1,4-benzoksazinila, 2H-1,4-benzoksazinila, 2H-3,1-benzoksazinila, 1H-2,1-benzotiazinila, 1H-2,3-benzotiazinila, 2H-1,2-benzotiazinila, 2H-1,3-benzoti-azinila, 2H-1,4-benzotiazinila, 2H-3,1-benzotiazinila, cinolinila, ftalazinila, kvinazolinila, kvinoksalinila, izokvinolila, kvinolila, 1H-2-benzopiranila, 2H-1-benzopiranila, 1H-2-benzotiopiranila ili 2H-1-benzotiopiranila.
R1 koji znači zasićen ili djelomično zasićen pet- do šesteročlani prsten koji sadrži jedan ili dva hetero atoma odabranih iz O, S ili skupinu N-R9 uključuje skupine u kojima je R1 skupina –CRaRb i skupine u kojima je R1 skupina –NRaRb, u kojoj Ra i Rb zajedno tvore pet- do šesteročlani zasićeni ili djelomično zasićeni prsten koji opcionalno sadrži dodatnu N-R9 skupinu ili atom O ili S, npr. skupine poput piperidinila, piperazinila, N-(hidroksi-C1-6-alkilpiperazinila, morfolinila, tiomorfolinila, pirolidinila, tetrahidropiridila, tetrahidropiranila, tetrahidrofuranila itd.
Kiselinske soli spojeva prema ovom izumu su farmaceutski prihvatljive soli nastale iz neotrovnih kiselina. Primjeri takvih organskih soli su one s maleinskom, fumarnom, benzojevom, askorbinskom, jantarnom, oksalnom, bimetilensalicilnom, metansulfonskom, etandisulfonskom, octenom, propi-onskom, vinskom, salicilnom, limunskom, glukonskom, mliječnom, jabučnom, bademovom, cinamičnom, citrakonskom, asparaginskom, stearinskom, palmi-tinskom, itakonskom, glikolnom, p-aminobenzojevom, glutaminskom, benzen-sulfonskom i teofilinskom octenom kiselinom, kao i 8-haloteofilini, na primjer 8-bromoteofilin. Primjeri takvih anorganskih soli su one sa solnom, hidrobromnom, sumpornom, sulfaminskom, forsornom i dušičnom kiselinom.
Farmaceutske smjese prema ovom izumu ili one koje su proizvedene u skladu s ovim izumom mogu se primjenjivati na bilo koji prikladan način, na primjer oralno u obliku tableta, kapsula, prašaka, sirupa itd. ili parenteralno u obliku otopina za ubrizgavanje. Za pripremu takvih smjesa mogu se koristiti načini dobro poznati struci i mogu se upotrijebiti bilo koji farmaceutski prihvatljivi nositelji, otapala, ekscipijenti ili drugi aditivi koje struka normalno rabi.
Prikladno se spojevi prema ovom izumu primjenjuju u obliku jediničnih doza koje sadrže navedene spojeve u količini od oko 0,01 do 100 mg.
Ukupna dnevna doza obično se kreće između 0,05 - 500 mg, a najbolje od oko 0,1 do 50 mg aktivne tvari spoja prema ovom izumu.
Spojevi prema ovom izumu mogu se pripraviti kako slijedi:
1) Aklilacijom piperazina, piperidina ili tetrahidropirina formule II s alkilirajućim derivatom formule III:
[image]
u kojoj su R1-R8, X, W, n, m i točkasta crta prema ranijoj definiciji, a L je ostatak poput halogena, mesilata ili tosilata;
2) Reduktivnom alkilacijom amina formule II s reagensom formule IV:
[image]
u kojoj su R1-R8, X, W, n, m i točkasta crta prema ranijoj definiciji, a E je aldehid ili aktivna karboksilna kiselina;
3) Redukcijom dvostruke veze u prstenu tetrahidropiridinila u derivatima formule V:
[image]
u kojoj su R1-R8, W, n i m prema ranijoj definiciji;
4) Acilacijom amina formule VI
[image]
u kojoj su R1-R8, X, W, n, m i točkasta crta prema ranijoj definiciji, uporabom karboksilne i kopulirajućeg agensa, aktivnog estera, kiselog klorida, izocijanata, karbamoil klorida ili dvofaznim postupkom tretiranjem s fozgenom i potom dodavanjem amina;
5) Cijepanjem derivata veze polimera formule VII
[image]
u kojoj su R1-R7, X, W, n i m prema ranijoj definiciji, a R'OH je hidroksietil ili hidroksimetil polistiren, Wangova smola ili analogne polietilen glikol polistirenske smole; nakon čega se spoj formule I izolira kao slobodna baza ili njezina farmaceutski prihvatljiva kiselinska sol.
Aliklacija prema načinu 1) prikladno se provodi u inertnom organskom otapalu poput podobno kipućeg alkohola ili ketona, preferirano uz prisutnost organske ili anorganske baze (kalijev karbonat, diizopropiletilamin ili trietilamin) na temperaturi refluksa. Alternativno, alkilacija se može provesti na fiksnoj temperaturi koja je različita od vrelišta, u jednom od gore spomenutih otapala ili u dimetil formamidu (DMF), dimetilsulfoksidu (DMSO) ili N-metilpirolidinu-2-jedan (NMP), preferirano uz prisutnost baze. Sinteza amina formule II, 3-(piperidin-4-il)-1H-indola i 3-(3,6-dihidro-2H-piridin-4-il)-1H-indola, opisana je u literaturi (vidi EP-A1-465398).
Alkilirajući derivati formule III pripravljaju se nitracijom alkilom supstituiranih feniloctenih kiselina te potom redukcijom nitro skupine, npr. s kositrenim(II) kloridom i funkcionalizacijom dobivene amino skupine. Nakon toga se karboksilna kiselina reducira u odgovarajući alkohol, npr. tretiranjem s boranom i potom konverzijom alkohola u ostatak, npr. tretiranjem s metan sulfonil kloridom ili tionil bromidom.
Reduktivna alkilacija prema načinu 2) provodi se prema standardnim načinima iz literature. Reakcija se može provesti u dvije faze, npr. kopulacijom amina formule II s reagensom formule IV na standardne načine preko klorida karboksilne kiseline, aktivnih estera ili primjenom karboksilnih kiselina u kombinaciji s kopulirajućim reagensom poput npr. dicikloheksil karbodiimida, te potom redukcijom dobivenog amida s litij aluminijevim hidridom ili alanom. Karboksilna kiselina formule IV pripravlja se nitracijom alkilom supstituirane feniloctene kiseline i zatim redukcijom nitro skupine, npr. s kositrenim(II) kloridom i konačno funkcionalizacijom dobivene amino skupine.
Reakcija se može provesti i standardnim postupkom u jednoj posudi, npr. pomoću reduktivne aminacije amina formule II i aldehida formule IV. Aldehidi formule IV pripravljaju se redukcijom ranije spomenute funkcionalizirane (aminofenil)octene kiseline tretiranjem s reducirajućim agensom poput npr. boranom. Dobiveni se alkohol konvertira u odgovarajući aldehid na standardne načine oksidacije, npr. piridinij klorokromatom.
Redukcija dvostruke veze prema načinu 3) obično se obavlja katalitičkom hidrogenacijom pri niskom tlaku (< 3 atm.) u Paarovom uređaju ili uporabom reducirajućih agensa poput diborana ili hidrobornih derivata pripravljenih in situ iz NaBH4 u trifluorooctenoj kiselini u inertnim otapalima poput tetrahidrofurana (THF), dioksana ili dietil etera.
Acilacija prema načinu 4) prikladno se provodi na standardne načine preko klorida karboksilne kiseline, aktivnih estera ili primjenom karboksilnih kiselina u kombinaciji s kopulirajućim reagensima poput npr. dicikloheksil karbodiimida. Kad acilacija proizvede derivate uree, acilirajući reagens su karbamoil kloridi, izocijanati ili dvofazni postupak koji se sastoji od tretiranja fozgenom i potom dodavanjem amina.
Spojevi intermediera formule VI pripravljaju se prema opisu u načinu 1) i 2).
Derivati strukture VII pripravljaju se pomoću sekvence sinteze čvrste faze prema donjem prikazu. Konačni proizvod odcijepljen je od smole prema načinu 5) pomoću otopljenog natrijevog metoksida u mješavini metanola i tetrahidrofurana na sobnoj temperaturi. Prvi strukturni blok, VIII, pripravljen tert-butoksikarbonilnom zaštitom spojeva formule II, koja se priprema na načine poznate kemičarima od struke (vidi također EP-A1-465398), općenito se veže na smolu (npr. polistirenom vezani etil 4-nitrofenil karbonat) pomoću baze (npr. N,N-dimetilaminopiridin i N,N-diizopropiletilamin) na povišenoj temperaturi (npr. 50-100°C) u aprotičkom otapalu (npr. DMF ili DMSO). Nakon deprotekcije spoja IX trifluorooctenom kiselinom, alkilacijom spoja X uvodi se drugi različiti strukturni blok, pri čemu nastaje spoj XI. Alkilirajući se reagens pripravlja nitracijom alkilom supstituirane feniloctene kiseline prema standardnim postupcima nitracije, a potom redukcijom karboksilne kiseline, npr. tretiranjem boranom u tetrahidrofuranu i konačnom konverzijom dobivenog alkohola u ostatak, npr. tretiranjem metansulfonil kloridom u diklorometanu i trietilaminu. Alkilacija se provodi na povišenoj temperaturi (50-100°C) u aprotičkom otapalu poput DMF, acetona ili acetonitrila, što daje smolu XI. Nakon redukcije nitro skupine, npr. tretiranjem kositrenim(ii) kloridom u DMF, treći različiti strukturni blok uvodi se standardnim postupkom acilacije, npr. dodavanjem kiselog klorida, izocijanata ili karbamoil klorida i baze na niskoj temperaturi u DMF, diklorometan ili acetonitril.
[image]
R''=C(O)O(CH2)2(PS), PS = Wangova smola, R1, R7, X, W, n i m prema gornjoj definiciji.
Pokusi
Tališta su određivana na uređaju Büchi SMP-20 i nisu korigirana. Analitičli LC-MS podaci dobiveni su na instrumentu PE Sciex API 150EX opremljenom IonSpray izvorom i Shimadzu LC-8A/SLC-10A LC sustavom. LC uvjeti (C18 kolona 4,6 x 30 mm s veličinom čestica 3,5 μm) bili su linearna gradijentna elucija s vodom/acetonitrilom/trifluorooctenom kiselinom (90:10:0,05) u vodu/ acetonitril/trifluorooctenu kiselinu (10:90:0,03) za 4 min pri 2 mL/min. Čistoća je određivana integracijom UV traga (254 nm). Vremena retencije, Rt, izražena su u minutama.
Maseni spektri dobiveni su metodom alternativnog skeniranja radi dobivanja podataka o težini. Molekularni ion, MH+, dobiven je na niskoj voltaži otvora (5-20V), a fragmentacija na visokoj voltaži otvora (100-200V).
Preparativna LC-MS separacija provedena je na istom instrumentu. LC uvjeti (C18 kolona 20 x 50 mm s veličinom čestica 5 μm) bili su linearna gradijentna elucija s vodom/acetonitrilom/trifluorooctenom kiselinom (80:20:0,05) u vodu/ acetonitril/tribluorooctenu kiselinu (5:95:0,03) za 7 min pri 22,7 mL/min. Prikupljanje frakcije obavljeno je pomoću "split-flow" MS detekcije.
1H NMR spektri registrirani su pri 500,13 MHz na instrumentu Bruker Avance DRX500 ili pri 250,13 MHz na instrumentu Bruker AC 250. Kao otapala su korišteni deuterizirani kloroform (99,8%D) ili dimetil sulfoksid (99,9%D). TMS je služio kao interni referentni standard. Vrijednosti kemijskih pomaka izražene su u ppm-vrijednostima. Za multiplicitet NMR signala koriste se sljedeće kratice: s=singlet, d=dublet, t=triplet, q=kvartet, qui=kvintet, h=heptet, dd=dvostruki dublet, dd=dvostruki triplet, dq=dvostruki kvartet, tt= trostruki triplet, m=multiplet. NMR signali koji odgovaraju kiselinskim protonima općenito su izostavljeni. Sadržaj vode u spoju u kristalnom obliku određivan je Karl Fischerovom titracijom. Za kromatografiju u koloni korišten je silikagel tipa Kieselgel 60, 40-60 mesh ASTM. Za kromatografiju ionskom izmjenom (SCX, 1g, Varian Mega Bond Elut®, Chrompack kat. br. 220776). Prije uporabe SCX kolona je prekondicionirana 10%-tnom otopinom octene kiseline u metanolu (3 mL).
Primjeri
Priprava intermediera
A. Acilirajući reagens
(2-Metil-5-nitrofenil)octena kiselina
Tikvica s okruglim dnom od 1 L napunjena je koncentriranom sumpornom kiselinom (500 mL) i ohlađena na -12°C (etilenglikol - suhi led). Tijekom 10 min dodavana je (2-metilfenil)octena kiselina (35,4 g, 0,24 mol) otopljena u diklorometanu (120 mL), a potom je mješavina tijekom dva sata kap po kap tretirana ranije ohlađenom (etilen glikol - suhi led) otopinom koncentrirane sumporne kiseline (100 mL) i 100%-tne dušične kiseline (10 mL). Reakcijska mješavina 1 sat je miješana na -12°C, a potom ulivena na led. Vodena faza ekstrahirana je etil acetatom (3 x 1 L). Kombinirane organske faze isprane su matičnim lugom (2 x 1L) i vodom (2 x 1L), osušene (Na2SO4) i koncentrirane in vacuo te je dobiveno 38,1 g sirove mješavine (38 g). 1H NMR je dao 70:30 mješavinu spoja iz naslova i (2-metil-3-nitrofenil)octenu kiselinu, a spoj iz naslova pročišćen je trituacijom s dietil eterom.
B. Alkilirajući reagensi
2-(2-Metansulfoniloksietil)-1-metil-4-nitrobenzen
Tikvica s okruglim dnom od 500 mL napunjena je (2-metil-5-nitrofenil)octenom kiselinom (15 g, 77 mmol) i suhim THF (300 mL). Mješavina je ohlađena ledenom vodom i tijekom jednog sata kap po kap tretirana boran-tetrahidrofuran kompleksom (90 mL, 1M u THF, 90 mmol). Reakcijska mješavina je dva sata miješana na sobnoj temperaturi i zatim ulivena na led. Vodena faza ekstrahirana je etil acetatom (3 x 600 mL). Kombinirane organske faze isprane su matičnim lugom (2 x 1L) i vodom (2 x 1L), osušene (Na2SO4) i koncentrirane in vacuo. Talog je ponovno otopljen u diklorometanu (200 mL) i trietilaminu (10,8 mL, 78 mmol). Mješavina je ohlađena ledenom vodom i tijekom 20 min joj je dodavana mješavina metansulfonil klorida (6,05 mL, 78 mmol) otopljenog u diklorometanu (100 mL). Reakcijska mješavina je 2 sata miješana na sobnoj temperaturi. Reakcijska mješavina koncentrirana je in vacuo. Talog je pročišćen flash komatografijom na silikagelu (eluent: etil acetat/heptan 2:3) kako bi se dobio spoj iz naslova (7,8 g). 1H NMR (CDCl3): 2,45 (s,3H); 2,96 (s,3H); 3,15 (t,2H); 4,45 (t,2H); 7,33 (d,1H); 7,98-8,11 (m,2H).
2-(2-Bromoetil)-1-metil-4-nitrobenzen
Mješavina 2-(2-metansulfoniloksietil)-1-metil-4-nitrobenzena (4,0 g) i litijevog bromida (6,6 g) u acetonu (250 mL) 31⁄2 sata je kipjela pod refluksom. Dobivena mješavina je ohlađena i profiltrirana. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/heptan 1:2) kako bi se dobio spoj iz naslova (3,7 g). 1H NMR (DMSO-d6): 2,45 (s,3H); 3,25 (t,2H); 3,80 (t,2H); 7,50 (d, 1H); 8.05 (dd,1H); 8,25 (d,1H).
Priprava krutih nosača intermediera
Priprava 4-nitrofeniloksikarboniloksietil polistirena
Tikvica s okruglim dnom od 2 L napunjena je hidroksietil polistirenom (6,9 g, 83 mmol, komercijalno raspoloživom od Rapp Polymere, kat. br. HA 1 400 00), N-metil-morfolinom (20 mL, 182 mmol) i suhim diklorometanom (900 mL). Suspenzija je ohlađena na ledenoj kupki, a potom joj je tijekom 5 min dodavan 4-nitrofenil kloroformiat, otopljen u suhom diklorometanu (400 mL). Mješavina je 16 h miješana na sobnoj temperaturi. Smola je profiltrirana i isprana suhim diklorometanom (5 x 200 mL). Smola je osušena in vacuo (20°C, 72 h), kako bi se dobila smola iz naslova (79,6 g).
Priprava polimerom vezanog 3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-5-fluoro-1H-indola
Tikvica s okruglim dnom od 100 mL napunjena je 4-nitrofenil-oksikarboniloksietil polistirenom (6,6 g, 7,1 mmol), 5-fluoro-3-(1-tert-butoksikarbonilpiperidin-4-il)-1H-indolom (2,7 g, 8,1 mmol), diizopropil-etilaminom (6,2 mL, 35,6 mmol), 4-dimetilaminopiridinom (0,87 g, 7,1 mmol) i suhim dimetil formamidom (85 mL). Mješavina je 20m h miješana na 90°C. Nakon hlađenja na sobnu temperaturu, smola je profiltrirana i isprana suhim dimetil formamidom (3 x 25 mL), suhim acetonitrilom (3 x 25 mL) i suhim diklorometanom (3 x 25 mL). Smola je prebačena u stakleni cilindar od 250 mL s trostrukim odvodom. Potom je smola 20 min tretirana s 80 mL 1:1 mješavine diklorometana i trifluorooctene kiseline koja sadrži anis (2%, w/w) i metionina (0,2%, w/w) pomoću protoka dušika radi protresanja smole (Oprez: Stvaranje ugljikovog dioksida). Smola je profiltrirana i isprana suhim diklorometanom (25 mL), 1:1 mješavinom diklorometana i trietilamina (3 x 25 mL) i suhim diklorometanom (3 x 25 mL). Smola je prebačena u tikvicu s okruglim dnom od 150 mL. Dodan je acetonitril (70 mL), diizopropiletilamin (5,2 mL, 30 mmol) i 2-(2-metansulfoniloksietil)-1-metil-4-nitrobenzen (3,67 g, 14 mmol). Reakcijska mješavina 18 h je grijana na 70°C. Nakon hlađenja na sobnu temperaturu smola je profiltrirana i isprana suhim acetonitrilom (3 x 25 mL) i suhim diklorometanom (3 x 25 mL). Smola je prebačena u tikvicu od 250 mL s okruglim dnom i tretirana dihidratom kositrenog(II) klorida (60 mL 0,5 M otopine in DMF). Reakcijska mješavina je 18 h miješana na sobnoj temperaturi. Smola je profiltrirana i isprana suhim dimetil formamidom (3 x 25 mL), suhim acetonitrilom (3 x 25 mL) i suhim diklorometanom (3 x 25 mL). Smola je osušena in vacuo (20°C, 20 h) i dobiven je spoj iz naslova (6,3 g).
Na sličan su način pripravljeni slijedeći polimerom vezani spojevi:
3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-5-kloro-1H-indol
3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-6-kloro-1H-indol
3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-7-kloro-1H-indol
Priprava spojeva prema ovom izumu
Primjer 1
1a, 3-(1-{2-[5-(Acetilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indol, fumerat
Mješavina (2-metil-5-nitrofenil)octene kiseline (47 g) i tionil klorida (62 mL) u diklorometanu (400 mL) 5 h je kipjela pod refluksom i potom je koncentrirana in vacuo. Mala količina smole (5 g) otopljena je u tetrahidrofuranu (100 mL) i kap po kap dodana mješavini 6-kloro-3-(3,6-dihidro-2H-piridin-4-il)-1H-indola (6,0 g) i trietilamina (5 mL) u tetrahidrofuranu (250 mL) na 0°C tijekom 10 min. Mješavina je koncentrirana in vacuo, dodana je vodena otopina 2N natrijevog hidroksida (400 mL) i etil acetata, nakon čega se istaložio 6-kloro-3-{1-[2-(2-metil-5-nitrofenil)-1-oksoetil]-3,6-dihidro-2H-piridin-4-il}-1H-indol koji je prikupljen filtracijom (3,7 g). Organske faze su izolirane, isprane matičnim lugom, osušene (Na2SO4), filtrirane i koncentrirane in vacuo. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/heptan 2:1) i dobivena je još jedna partija 6-kloro-3-{1-[2-(2-metil-5-nitrofenil)-1-oksoetil]-3,6-dihidro-2H-piridin-4-il}-1H-indola (2,2 g). Mješavina 6-kloro-3-{1-[2-(2-metil-5-nitrofenil)-1-oksoetil]-3,6-dihidro-2H-piridin-4-il}-1H-indola (5,3 g) u tetrahidrofuranu (100 mL) i dihidratu kositrenog(II) klorida (14,6 g) u etanolu kipjela je 2 h pod refluksom, a otapalo je in vacuo reducirano na oko 100 mL. Dodana je vodena otopina amonijaka i organska faza je odstranjena in vacuo. Vodena je faza ekstrahirana etil acetatom, a kombinirane organske faze isprane su matičnim lugom, osušene (Na2SO4), filtrirane i koncentrirane in vacuo kako bi se dobio 6-kloro-3-{1-[2-(5-amino-2-metilfenil)-1-oksoetil]-3,6-dihidro-2H-piridin-4-il}-1H-indol (5,1 g). Taj je spoj otopljen u tetrahidrofuranu (200 mL) i tijekom 10 min kap po kap dodavan suspenziji litij aluminijevog hidrida (1,5 g) u tetrahidrofuranu (100 mL) na 10°C. Dobivena mješavina 16 h je miješana na sobnoj temperaturi i podvrgnuta standardnom postupku obrade radi dobivanja sirovog 6-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]-3,6-dihidro-2H-piridin-4-il}-1H-indola (7,5 g, uključivo tetrahidrofuran). Sirovi spoj (4,0 g) otopljen je u octenoj kiselini (100 mL), a potom mu je dodan platinski oksid (400 mg), te je dobivena mješavina 6 h protresana pod 3 atmosfere vodika na sobnoj temperaturi. Mješavina je profiltrirana i dodana joj je voda (400 mL), a potom je do bazičnog pH dodana vodena otopina amonijaka. Vodena faza ekstrahirana je etil acetatom, a kombinirana organska faza isprana matičnim lugom, osušena (Na2SO4), profiltrirana i koncentrirana in vacuo kako bi se dobio 6-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indol (2,4 g). Spoj je otopljen u tetrahidrofuranu (200 mL) i trietilaminu (1 mL), a mješavina je ohlađena na 0°C te joj je kap po kap dodan acetil klorid (0,5 mL) u diklorometanu (30 mL). Dobivena mješavina je 2 h miješana na sobnoj temperaturi, profiltrirana i koncentrirana in vacuo. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/etanol/trietilamin 80:20:4) kako bi se dobio sirovi spoj iz naslova u obliku fumeratne soli iz etanola (0,7 g). Mp 164-166°C. 1H NMR (DMSO-d6): 1,85-2,10 (m,4H); 2,25 (s,3H); 2,65-3,00 (m,7H); 3,30-3,45 (m,2H); 6,60 (s,3H (fumerat)); 7,00 (dd,1H); 7,10 (d,1H); 7,20 (d,1H); 7,30-7,45 (m,3H); 7,65 (d,1H); 9,85 (s,1H); 11,05 (s,1H). MS m/z: 410 (MH+), 259, 247, 176.
Primjer 2
2a, 3-(1-{2-[5-(Ciklobutilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol, oksalat
Mješavina 5-fluoro-3-(piperidin-4-il)-1H-indola (2,7 g) u dimetil formamidu (75 mL), 2-(2-bromoetil)-1-metil-4-nitrobenzena (3,7 g) u butanonu (200 mL) i trietilaminu (9,3 mL) kipjela je 20 h pod refluksom, a dobivena mješavina je koncentrirana in vacuo. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/trietilamin 100:4) kako bi se dobio 5-fluoro-3-{1-[2-(2-metil-5-nitrofenil)etil]piperidin-4-il}-1H-indol (3,6 g), koji je potom otopljen u octenoj kiselini (25 mL) te mu je dodan etanol (75 mL) i platinasti oksid (50 mg). Dobivena mješavina protresana je 3 h pod 3 atmosfere vodika na sobnoj temperaturi. Mješavina je reducirana in vacuo (50 mL), ulivena u ledenu vodu, a potom je do bazičnog pH dodana vodena otopina amonijaka. Vodena faza ekstrahirana je mješavinom etil acetata/tetrahidrofurana, a kombinirana organska faza isprana matičnim lugom, osušena (MgSO4), profiltrirana i koncentrirana in vacuo. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/etanol/trietilamin 100:4:4) i dobiven je 3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-5-fluoro-1H-indol (1,0 g), koji je zatim otopljen u tetrahidrofuranu (45 mL) i trietilaminu (1,3 mL) na 5°C, nakon čega mu je dodan ciklobutankarbonil klorid (0,3 g) u tetrahidrofuranu (15 mL). Dobivena mješavina miješana je 1 h na 5°C, profiltrirana i koncentrirana in vacuo. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/ etanol/trietilamin 100:4:4) kako bi se dobio sirovi proizvod koji je izoliran kao oksalatna sol iz etil acetata u bijelom kristalnom obliku (0,7 g). Mp 116-125°C. 1H NMR (DMSO-d6): 1,75-1,85 (m,1H); 1,85-2,05 (m,3H); 2,05-2,25 (m,6H); 2,30 (s,3H); 2,90-3,25 (m,8H); 3,65 (d,2H); 6,85-6,95 (m,1H); 7,10 (d,1H); 7,25 (s,1H); 7,30-7,40 (m,2H); 7,40 (d,1H); 7,55 (s,1H); 9,65 (s,1H); 11,00 (s,1H). MS m/z: 434 (MH+).
Primjer 3
3a, 3-(1-{2-[5-(Acetilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol:
Polimerom vezan 3-[1-(2-{5-amino-2-metilfenil}etil)piperidin-4-il]-5-fluoro-1H-indol (100 g, 100 μmol), trietilamin (90 μL) i dimetilaminopiridin (0,50 mL 0,2 M otopine suhog acetonitrila) miješani su u reakcijskoj cijevi. Mješavina je ohlađena na 0°C i tretirana acetil kloridom (0,50 mL 1M otopine u suhom acetonitrilu). Reakcijska mješavina ostavljena je 2 h na 0°C. Smola je profiltrirana i isprana suhim acetonitrilom (3 x 1 mL). Smola je 1 h tretirana 1 mL mješavine natrijevog metoksida (2 mL, 5 N natrijevog metoksida u metanolu), metanola (50 mL) i tetrahidrofurana (50 mL). Nakon filtriranja smola je isprana metanolom (mL). Kombinirani filtrati napunjeni su u prekondicioniranu kolonu s ionskom izmjenom (500 mg SCX kolona, komercijalno raspoloživa od Analytical Instruments, dio br. 1210-2040), isprani acetonitrilom (1 mL) i metanolom (1 mL). Proizvod je eluiran s 4 M amonijaka u metanolu. Uparavanjem hlapivih otapala dobiven je spoj iz naslova u obliku žutog ulja (6 mg, 15 μmol). LC/MS (m/z) 394 (MH+), RT = 1,98, čistoća: 88%.
Na sličan su način pripravljani spojevi koji slijede. Kad su pripravljane uree umjesto kiselog klorida rabio se odgovarajući karbamoil klorid. Spojevi su pročišćeni preparativnom kromatografijom s povratnom fazom HPCL ako je UV trag (254 nm) pokazivao manje od 70% čistoće od očekivane mase. Dobivena otopina potom je napunjena u prekondicioniranu kolonu s ionskom izmjenom ispranom acetonitrilom (1 mL) i metanolom (1 mL). Proizvod je eluiran s 4 M amonijaka u metanolu, a otopina koncentrirana in vacuo radi dobivanja konačnog proizvoda.
3b, 3-(1-{2-[2-Metil-5(tiofen-1-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-kloro-1H-indol: LC/MS (m/z) 478 (MH+), RT = 2,45, čistoća: 74%.
3c, 3-(1-{2-[2-Metil-5-(3-metoksibenzoilamino)fenil]etil}piperidin-4-il)-5-kloro-1H-indol: LC/MS (m/z) 502 (MH+), RT = 2,51, čistoća: 86%.
3d, 3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 420 (MH+), RT = 2,16, čistoća: 97%.
3e, 3-(1-{2-[2—Metil-5-(tiofen-2-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 462 (MH+), RT = 2,33, čistoća: 91%
3f, 3-(1-{2-[5-(Izobutanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 422 (MH+), RT = 2,20. čistoća: 93%.
3g, 3-(1-{2-[2-Metil-5-(pivaloilamino)fenil]etil}piperidin-4-il)-5-flurofo-1H-indol: LC/MS (m/z) 436 (MH+), RT = 2,33, čistoća: 95%.
3h, 3-(1-{2-[5-Heksanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 450 (MH+), RT = 2,48, čistoća: 95%.
3i, 3-(1-{2-[5-(4-Fluorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 474 (MH+), RT = 4,02, čistoća: 95%.
3j, 3-(1-{2-[5-(3-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol LC/MS (m/z) 486 (MH+), RT = 2,41, čistoća: 91%
3k, 3-(1-{2-[2-Metil-5-(piridin-3-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 457 (MH+), RT = 1,90, čistoća: 80%.
3l, 3-(1-{2-[2-Metil-5-(3-fenilpropanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 484 (MH+), RT = 2,47, čistoća: 96%.
3m, 3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 470 (MH+), RT = 2,47, čistoća: 90%.
3n, 3-(1-{2-[2-Metil-5-(3-metil-3-fenilureido)fenil]etil}piperidin-4-il)-6-kloro-1H-indol: LC/MS (m/z) 501 (MH+), RT = 2,51, čistoća: 87%.
3o, 3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indol: LC/MS (m/z) 436 (MH+), RT = 2,30, čistoća: 96%
3p, 3-(1-{2-[2-Metil-5-(tiofen-2-ilmetanoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indol: LC/MS (m/z) 478 (MH+), RT = 2,44, čistoća: 93%.
3q, 3-(1-{2-[5-(Izobutanoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indol: LC/MS (m/z) 438 (MH+), RT = 2,33 čistoća: 96%.
3r, 3-(1-{2-[5-(3-Metoksibenzoilemino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-inodl: LC/MS (m/z) 502 (MH+), RT = 2,51, čistoća: 93%.
3s, 3-(1-{2-[2-Metil-5-(piridin-3-ilmetanoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indol: LC/MS (m/z) 473 (MH+), RT = 2,03, čistoća: 88%.
3t, 3-[1-(2-{5-[2-Metoksifenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-6-kloro-1H-indol: LC/MS (m/z) 516 (MH+), RT = 2,52, čistoća: 94%.
3u, 3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indol: LC/MS (m/z) 486 (MH+), RT = 2,58, čistoća: 93%.
3v, 3-[1-(2-{5-[(Ciklopentilmetanoil)amino]-2-metilfenil}etil)piperidin-4-il]-6-kloro-1H-indol: LC/MS (m/z) 465 (MH+), RT = 2,49, čistoća: 95%.
3x, 3-(1-{2-[2-Metil-5-(morfolin-4-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 465 (MH+), RT =3,27, čistoća: 91%.
3y, 3-[1-(2-{5-[3-(4-Fluorofenil)ureido]-2-metilfenil}etil)piperidin-4-il]-5-fluoro-1H-indol: LC/MS (m/z) 504 (MH+), RT = 2,52, čistoća: 92%.
3z, 3-(1-{2-[5-(Heksanoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indol: LC/MS (m/z) 466 (MH+), RT = 2,55, čistoća: 88%.
3aa, 3-(1-{2-[2-Metil-5-(tetrahidrofuran-4-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 464 (MH+), RT = 2,05, čistoća: 96%.
3ab, 3-(1-{2-[5-(4-Klorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indol: LC/MS (m/z) 506 (MH+), RT = 2,62, čistoća: 87%.
3ac, 3-(1-{2-[5-(3-Cikloheksilpropanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indol: LC/MS (m/z) 490 (MH+), RT = 2,76, čistoća: 95%.
3ad, 3-[1-(2-{5-[(3-Fenilpropanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indol: LC/MS (m/z) 500 (MH+), RT = 2,56, čistoća: 91%.
3ae, 3-[1-(2-{5-[(2-Feniletanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indol: LC/MS (m/z) 486 (MH+), RT = 2,48, čistoća: 92%.
3af, 3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-7-kloro-1H-indol: LC/MS (m/z) 486 (MH+), RT = 2,54, čistoća: 89%.
3ag, 3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indol: LC/MS (m/z) 436 (MH+), RT = 2,26, čistoća: 93%.
Primjer 4
4a, 3-[1-(2-{5-[2-(4-Fluorofenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indol
Mješavina (2-metil-5-nitrofenil)octene kiseline (2,5 g) i 1,1'-karbonildiimidazola (2,1 g) u dimetil formamidu (50 mL) 15 min je miješana na sobnoj temperaturi i potom joj je dodana otopina 7-kloro-3-(piperidin-4-il)-1H-indola (3,0 g) u dimetil formamidu (50 mL). Dobivena mješavina miješana je 1 h na sobnoj temperaturi i ulivena na ledenu vodu. Spoj je izoliran filtriranjem i otopljen u tetrahidrofuranu. Organska je faza isprana matičnim lugom, osušena (MgSO4), profiltrirana i koncentrirana in vacuo kako bi se dobio 7-kloro-3-{1-[2-(2-metil-5-nitrofenil)-1-oksoetil]-piperidin-4-il}-1H-indol (4,7 g). Mješavina 7-kloro-3-{1-[2-(2-metil-5-nitrofenil)-1-oksoetil]-piperidin-4-il}-1H-indola (16,6 g) i etanola (500 mL) grijana je do temperature refluksa i potom joj je tijekom 30 min dodavana koncentrirana HCl (22 mL) i željezni prah (11,3 g). Dobivena mješavina još je 90 min kipjela pod refluksom, vruća je profiltrirana i koncentrirana in vacuo. Talog je otopljen u tetrahidrofuranu, a organska faza je isprana matičnim lugom, osušena (MgSO4), profiltrirana i koncentrirana in vacuo kako bi se dobio 7-kloro-3-{1-[2-(5-amino-2-metilfenil)-1-oksoetil]-piperidin-4-il}-1H- indol (14,3 g). Suspenzija litij aluminijevog hidrida (6,4 g) u tetrahidrofuranu (250 mL) ohlađena je (5°C) i potom joj je dodana mješavina 7-kloro-3-{1-[2-(5-amino-2-metilfenil)-1-oksoetil]-piperidin-4-il}-1H-indola (16,0 g) u tetrahidrofuranu (250 mL). Dobivena mješavina 90 min je kipjela pod refluksom, ohlađena na 5°C i ugašena dodavanjem vode. Mješavina je osušena (MgSO4), miješana 10 min, profiltrirana i koncentrirana in vacuo kako bi se dobio 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indol (12,4 g). Otopina 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola (1,0 g) i N-etildiizopropilamina (0,7 g) u tetrahidrofuranu (25 mL) ohlađena je (5°C) i zatim joj je dodana otopina (4-fluorofenil)octenog klorida u tetrahidrofuranu (25 mL). Dobivena mješavina 1 h je miješana nas sobnoj temperaturi, a zatim je ulivena u matični lug. Vodena faza je ekstrahirana tetrahidrofuranom, a kombinirane organske faze su osušene (MgSO4), profiltrirane i koncentrirane in vacuo. Talog je pročišćen flash kromatografijom na silikagelu (eluent: etil acetat/heptan/trietilamin 70:30:5) i dobiven je proizvod (0,81 g). LC/MS (m/z) 504 (MH+), RT = 2,45, čistoća: 62%.
Na sličan su način pripravljeni sljedeći spojevi:
4b, 3-[1-(2-{5-[2-Metoksifenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]pipridin-4-il}-1H-indola i (4-metoksifenil)acetil klorida. LC/MS (m/z) 516 (MH+), RT = 2,35, čistoća: 61%.
4c, 3-[1-(2-{5-[(Ciklobutilmetanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola i ciklobu-tankarbonil klorida. LC/MS (m/z) 450 (MH+), RT = 2,19, čistoća: 62%.
4d, 3-(1-{2-[5-(benzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil(etil]piperidin-4-il}-1H-indola i benzil klorida. LC/MS (m/z) 472 (MH+), RT = 2,47, čistoća: 94%.
4e, 3-(1-{2-[5-(4-Fluorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-3-metilfenil)etil]piperidin-4-il}-1H-indola i 4-fluorobenzoil klorida. LC/MS (m/z) 490 (MH+), RT = 1,40, čistoća:74%.
4f, 3-(1-{2-[5-(4-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola i 4-metoksibenzoil klorida. LC/MS (m/z) 502 (MH+), RT = 2,39, čistoća: 85%.
4g,3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola i nikotinoil klorida. LC/MS (m/z) 473 (MH+), RT = 1,85, čistoća: 75%.
4h, 3-[1-(2-{2-Metil-5-[(piridin-4-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola i izonikotinoil klorida. LC/MS (m/z) 473 (MH+), RT = 1,84, čistoća: 80%.
4i, 3-[1-(2-{2-Metil-5-[(tiofen-2-ilmetanol)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola i tiofen-2-karbonil klorida. LC/MS (m/z) 478 (MH+), RT = 2,34, čistoća: 95%.
4j, 3-[1-(2-{2-Metil-5-[(tiofen-3-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidin-4-il}-1H-indola i tiofen-3-karbonil klorida. LC/MS (m/z) 478 (MH+), RT = 2,31, čistoća: 77%.
4k, 3-[1-(2-{2-Metil-5-[(tiofen-2-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indol
iz 7-kloro-3-{1-[2-(5-amino-2-metilfenil)etil]piperidini-4-il}-1H-indola i [1,2,3] tiadiazol-5-karbonil klorda. LC/MS (m/z) 480 (MH+), RT = 2,24, čistoća: 69%.
Farmakološka ispitivanja
Spojevi prema ovom izumu ispitani su kroz vrlo priznate i pouzdane testove. Radi se o sljedećim testovima:
Inhibicija vezivanja [3H]YM-09151-2 na ljudske receptore dopamina D4
Tom se metodom in vitro određuje inhibicija lijekovima vezivanja [3H]YM-09151-2 (0,06 nM) na membrane ljudiskih kloniranih receptora dopamina D4.2 izraženih u CHO stanicama. Metoda je modificirana iz NEN Life Science Products, Inc., certifikat s tehničkim podacima PC2533-10/96. U tablici 1, koja slijedi, prikazani su rezultati ispitivanja:
Spoj % inhib. Spoj % inhib. Spoj % inhib.
3a 83 3q 97 3ag 95
3b 86 3r 88 4a 23a
3c 68 3s 92 4b 16a
3d 89 3t 75 4c 5a
3e 89 3u 86 4d 48
3f 96 3v 95 4e 44
3g 86 3x 90 4f 48
3h 83 3y 83 4g 6a
3j 90 3z 91 4h 73
3k 91 3aa 96 4i 85
3l 74 3ab 79 4j 48
3m 81 3ac 97 4k 67
3n 76 3ad 83
3o 99 3ae 89
3p 92 3af 90
Tablica 1: Podaci o vezivanju (% inhibicije vezivanja na 50 nM). aIC50 vrijednost
Našlo se da su spojevi prema ovom izumu jaki inhibitori vezivanja tritiiranog YM-09151-2 na receptore dopamina D4.
Spojevi su također ispitani u finkcionalnom pokusu opisanom od Gazi i sur. u Br. J. Pharmacol 1999., 128, 613-629. Kroz taj se test pokazalo da su spojevi djelomični agonisti ili antagonisti receptora dopamina D4.
Spojevi prema ovom izumu ispitani su i kroz slijedeće testove:
Inhibicija vezivanja [3H]Spiperona na D2 receptore
Spojevi su testirani s obzirom na afinitet prema receptoru dopamina D2 određivanjem njihove sposobnosti vezivanja [3H]Spiperona na D2 receptore pomoću metode prema Hyttel i sur. J. Neurochem. 1985., 44, 1615.
Inhibicija ponovnog preuzimanja [3H]Serotonina u sve sinaptosome mozga štakora
Spojevi su ispitani s obzirom na njihovo inhibirajuće djelovanje na ponovno preuzimanje 5-HT mjerenjem in vitro njihove sposobnosti inhibicije preuzimanja [3H]Serotonina u sve sinaptosome mozga štakora. Pokus je proveden prema opisu Hyttel Psychopharmacology 1978., 60, 13.
Inhibicija vezivanja [3H]Kentaserina na 5-HT2A receptore
Spojevi su ispitani s obzirom na njihov afinitet prema 5-HT2A receptorima određivanjem in vitro njihove sposobnosti inhibicije vezivanja [3H]Kentaserina (0,50 nM) na membrane mozga (korteksa) štakora. Metoda opisana u Sánchez i sur. Drug Dev. Res. 1991., 22, 239-250.
Djelovanje 5-HT2C receptora prema rezultatima fluorometrije
Spojevi su testirani s obzirom na njihovo djelovanje na 5-HT2C receptor izražen u CH stanicama prema rezultatima analize čitača fluorometrijske slike (FLIPR). Taj je pokus proveden prema uputama Molecular Devices Inc. Za njihov Clacium Assay Kit i modificiran iz Porter i sur. Br. J. Pharmacol. 1999., 128, 13.
Našlo se da ti spojevi nemaju znatnog ili imaju tek slabi afinitet prema receptoru dopamina D2. Za mnoge od spojeva utvrdilo se i da imaju afinitet prema 5-HT2A receptorima kao i inhibirajuće djelovanje prema ponovnom preuzimanju serotonina.
Tako se spojevi prema ovom izumu smatraju korisnima u liječenju pozitivnih i negativnih simptoma shizofrenije, drugih psihoza, tjeskobe, poput opće tjeskobe, panike i opsesivno kompulzivnog poremećaja, depresije, nuspojava izazvanih konvencionalnim antipsihotičkim agensima, migrenom, te za poboljšanje spavanja. Posebno se spojevi prema ovom izumu smatraju korisnima u liječenju pozitivnih i negativnih simptoma shizofrenije bez izazivanja ekstrapiramidalnih nuspojava.
Primjeri formulacije
Farmaceutske formulacije prema ovom izumu mogu se pripravljati na načine uobičajene u struci.
Na primjer: Tablete se mogu pripravljati miješanjem aktivnih tvari s običnim pomoćnim tvarima i/ili razrjeđivačima i potom komprimiranjem mješavine u konvencionalnom stroju za tabletiranje. Primjeri pomoćnih tvari i razrjeđivača su: škrobno brašno, krumpirov škrob, talk, magnezijev stearat, želatina, laktoza, vezivna sredstva i slično. Mogu se koristiti bilo koja pomoćna sredstva ili aditivi koji se uobičajeno rabe u svrhu bojanja, okusa, konzerviranja itd., pod uvjetom da budu kompatibilni s aktivnim tvarima.
Otopine za ubrizgavanje mogu se pripravljati otapanjem aktivne tvari i eventualnih aditiva u dijelu otapala za ubrizgavanje, preferirano sterilnoj vodi, uz podešavanje otopine na željeni volumen, sterilizaciju otopine i njezino punjenje u prikladne ampule ili bočice. Mogu se koristiti svi prikladni aditivi koje struka obično rabi, poput tonizirajućih agensa, konzervansa, antioksidansa itd.
Tipični primjeri formulacija prema ovom izumu:
Tablete koje sadrže 5,0 mg spoja prema ovom izumu kalkulirano kao slobodna baza:
Spoj 5,0 mg
Laktoza 60 mg
Kukuruzni škrob 30 mg
Hidroksipropilceluloza 2,4 mg
Mikrokristalinična celuloza 19, 2 mg
Kroskarmelozni natrij tipa A 2,4 mg
Magnezijev stearat 0,84 mg
Tablete koje sadrže 0,5 mg spoja prema ovom izumu kalkulirano kao slobodna baza:
Spoj 0,5 mg
Laktoza 46,9 mg
Kukuruzni škrob 23,5 mg
Povidon 1,8 mg
Mikrokristalinična celuloza 14,4 mg
Kroskarmelozni natrij tipa A 1,8 mg
Magnezijev stearat 0,63 mg
Sirup koji sadrži po mililitri:
Spoj 25 mg
Sorbitol 500 mg
Hidroksipropilcelulozu 15 mg
Glicerol 50 mg
Metil-paraben 1 mg
Propil-paraben 0,1 mg
Etanol 0,005 ml
Aromu 0,05 mg
Natrijev saharin 0,5 mg
Vodu do 1 ml
Otopina za ubrizgavanje koja sadrži po mililitri:
Spoj 0,5 mg
Sorbitol 5,1 mg
Octenu kiselinu 0,05 mg
Natrijev saharin 0,5 mg
Vodu do 1 ml
Claims (11)
1. Derivat supstituiranog indola naznačen time da ima formulu I
[image]
u kojoj je R1 vodik ili C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil ili C3-8-cikloalkil-C1-6-alkil, od kojih svi mogu jednom ili više puta biti supstituirani supstituentima odabranim iz halogena, cijano, nitro, amino, hidroksi, tiola, C1-6-alkoksi, C1-6-alkitio, trifluorometila, trifluorosulfonila i C1-6-alkilsulfonila ili je R1 aril, aril-C1-6-alkil, heteroarila, heteroaril-C1-6-alkila, pri čemu arilna i heteroarilna skupina može biti jednom ili više puta supstituirana supstituentima odabranima iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila ili R1 znači –NR'R'' pri čemu su R' i R'' neovisno odabrani iz vodika i C1-6-alkila, arila, aril-C1-6-alkila, heteroarila i heteroaril-C1-6-alkila, od kojih svi mogu jednom ili više puta biti supstituirani supstituentima odabranima iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, trifuorometila, trifluorometilsulfonila i C1-6-alkilsulfonila ili je R1 zasićeni ili djelomično zasićeni pet- do šesteročlani prsten koji sadrži jedan, dva ili tri hetero atoma odabranih iz O ili S i skupinu N-R9 u kojoj je R9 vodik ili C1-6-alkil opcionalno supstituiran supstituentima odabranima iz halogena, cijano, nitro, amino, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila;
W je veza ili O, S, CO, CS, SO ili SO2 skupina;
n je 0-6, m je 0-6, a n+m je 0-6; pod uvjetom da kad W znači O ili S n ≥ 2, a kad W znači CO, CS, SO ili SO2, n ≥ 1;
X je C, CH ili N, a točkasta crta koja počinje od X označava vezu ako X znači C i nepostojanje veze ako X znači N ili CH;
R2 je C1-6-alkil;
R3-R7 odabrani su iz vodika, halogena, cijano, nitro, amino, C1-6-alkila, C2-6-alkenila, C2-6-alkinila, C3-8-cikloalkila, C3-8-cikloalkil-C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, tiola, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila;
R8 je vodik, C1-6-alkil, C2-6-alkenil, C2-6-alkinil, C3-8-cikloalkil, C3-8-cikloalkil-C1-6-alkil, aril, aril-C1-6-alkil, acil, tioacil, C1-6-alkilsulfonil, trifluorometilsulfonil ili arilsulfonil ili njihove farmaceutski prihvatljive kiselinske soli.
2. Spoj prema patentnom zahtjevu 1,naznačen time da je u njemu indol vezan na X preko položaja 3 indola.
3. Spoj prema patentnim zahtjevima 1-2, naznačen time da je W veza.
4. Spoj prema patentnom zahtjevu 3, naznačen time da n+m znači 2.
5. Spoj prema patentnim zahtjevima 1-5, naznačen time da je R2 metilna skupina.
6. Spoj prema patentnim zahtjevima 1 ili 5, naznačen time da je skupina –NH-CO-R1 vezana na fenilnu skupinu na položaju suprotnom od položaja R2 skupine.
7. Spoj prema patentnim zahtjevima 1 ili 6, naznačen time da R1 znači C1-6 alkil, C3-8-cikloalkil, C3-8-cikloalkil-C1-6-alkil, fenil, fenil-C1-6-alkil, furanil, tienil, piridil, pirolil, pirimidil, pri čemu fenilne skupine mogu jednom ili više puta biti supstituirane supstituentima odabranima iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, trifluorometil, trifluorometilsulfonil i C1-6-alkilsulfonil ili R1 znači –NR'R'', gdje je jedan od R' i R'' vodik, a drugi od R' i R'' je odabran iz C1-6-alkila, fenila i fenil-C1-6-alkila, pri čemu fenilne skupine mogu biti jednom ili više puta supstituirane supstituentima odabranima iz halogena, cijano, nitro, amino, C1-6-alkila, C1-6-alkoksi, C1-6-alkitio, hidroksi, trifluorometila, trifluorometilsulfonila i C1-6-alkilsulfonila ili je R1 tetrahidropiranil ili morfolino, tiomorfolino, piperidino, piperazino ili N-(hidroksi-C1-6-alkil) piperazinil skupina.
8. Spoj prema patentnom zahtjevu 1, naznačen time da je odabran iz
3-(1-{2-[5-(Acetilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-(Ciklobutilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(Acetilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-/tiofen-2-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(3-metoksibenzoilamino)fenil]etil}piperidin-4-il)-5-kloro-1H-indola;
3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-tiofen-2-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(Izobutanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(pivaloilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(Heksanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(4-Fluorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(3-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(piridin-3-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(3-fenilpropanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[2-Metil-5-(3-metil-3-fenilureido)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(tiofen-2-ilmetanoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-Izobutanoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[5-(3-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(piridin-3-ilmetanoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-[1-(2-{5-[2-(4-Metoksifenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-6-kloro-1H-indola;
3-[1-(2-{5-[(Ciklopentilmetanoil)amino]-2-metilfenil}etil)piperidin-4-il]-6-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(morfolin-4-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-[1-(2-{5-[3-(4-Fluorofenil)ureido]-2-metilfenil}etil)piperidin-4-il]-5-fluoro-1H-indola;
3-(1-{2-[5-(Heksanoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(tetrahidrofuran-4-ilmetanoilamino)fenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-(1-{2-[5-(4-Klorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(3-Cikloheksilpropanoilamino)-2-metilfenil]etil}piperidin-4-il)-5-fluoro-1H-indola;
3-[1-(2-{5-[(3-Fenilpropanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{5-[(2-Feniletanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-(1-{2-[2-Metil-5-(4-metilbenzoilamino)fenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(Ciklopropilmetanoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-[1-(2-{5-[2-(4-Fluorofenil)etnoilamino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{5-[2-(4-Metoksifenil)etanoilamino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{5-[(Ciklobutilmetanoil)amino]-2-metilfenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-(1-{2-[5-(benzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(4-Fluorobenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-(1-{2-[5-(4-Metoksibenzoilamino)-2-metilfenil]etil}piperidin-4-il)-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-4-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(tiofen-2-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(tiofen-3-ilmetanoil)amino]fenil}etil)piperidin-4-il]-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(1-[1,2,3]tiadiazol-5-ilmetanoil)amino]fenil}etil)-piperidin-4-il]-7-kloro-1H-indola;
3-{1-[2-(5-Acetilamino-2-metilfenil)-etil]-3,6-dihidro-2H-piridin-4-il}-5-fluoro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)-amino]-fenil}-etil)-3,6-dihidro-2H-piridin-4-il]-5-fluoro-1H-indola;
3-[1-(2-{5-[(4-Fliorofenilmetanoil)-amino]-2-metilfenil}-etil)-3,6-dihidro-2H-piridin-4-il]-5-fluoro-1H-indola;
3-{1-[2-(5-Acetilamino-2-metilfenil)-etil]-3,6-dihidro-2H-piridin-4-il}-7-kloro-1H-indola;
3-[1-(2-{2-Metil-5-[(piridin-3-ilmetanoil)-amino]-fenil}-etil)-3,6-dihidro-2H-piridin-4-il]-7-kloro-1H-indola i
3-[1-(2-{5-[(4-Fluorofenilmetanoil)-amino]-2-metilfenil}-etil)-3,6-dihidro-2H-piridin-4-il]-7-kloro-1H-indola te njihovih farmaceutski prihvatljivih soli.
9. Farmaceutska smjesa, naznačena time da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 8 u terapeutski djelotvornoj količini, zajedno s jednim ili više farmaceutski prihvatljivih nositelja ili razrjeđivača.
10. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1 do 8, naznačena time da je za proizvodnju lijeka koirsnog u liječenju pozitivnih i negativnih simptoma shizofrenije, drugih psihoza, tjeskobe, poput opće tjeskobe, panike i opsesivno kompulzivnog poremećaja, depresije, agresije, nuspojava izazvanih konvencionalnim antipsihotičkim agensima, migrene, kognitivnih poremećaja, ADHD te za poboljšanje spavanja.
11. Način liječenja pozitivnih i negativnih simptoma shizofrenije, drugih psihoza, tjeskobe, poput opće tjeskobe, panike i opsesivno kompulzivnog poremećaja, depresije, agresije, nuspojava izazvanih konvencionalnim antipsihotičkim agenskima, kognitivnih poremećaja, ADHD i poboljšanja spavanja, naznačen time da se sastoji od primjene terapeutski prihvatljive količine spoja prema bilo kojem od patentnih zahtjeva 1 do 8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001123 | 2000-07-21 | ||
PCT/DK2001/000507 WO2002008223A1 (en) | 2000-07-21 | 2001-07-17 | Indole derivatives useful for the treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030015A2 true HRP20030015A2 (en) | 2005-02-28 |
Family
ID=8159625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030015A HRP20030015A2 (en) | 2000-07-21 | 2003-01-09 | Indole derivatives useful for the treatment of cns disorders |
Country Status (29)
Country | Link |
---|---|
US (1) | US6743809B2 (hr) |
EP (1) | EP1305307B1 (hr) |
JP (1) | JP2004504396A (hr) |
KR (1) | KR100851793B1 (hr) |
CN (1) | CN1264838C (hr) |
AR (1) | AR029858A1 (hr) |
AT (1) | ATE266024T1 (hr) |
AU (2) | AU2001281738B2 (hr) |
BG (1) | BG107528A (hr) |
BR (1) | BR0112998A (hr) |
CA (1) | CA2416212C (hr) |
CZ (1) | CZ301114B6 (hr) |
DE (1) | DE60103162T2 (hr) |
EA (1) | EA004749B1 (hr) |
ES (1) | ES2219554T3 (hr) |
HK (1) | HK1059782A1 (hr) |
HR (1) | HRP20030015A2 (hr) |
HU (1) | HUP0302820A3 (hr) |
IL (2) | IL153605A0 (hr) |
IS (1) | IS2172B (hr) |
MX (1) | MXPA02012927A (hr) |
NO (1) | NO323799B1 (hr) |
NZ (1) | NZ523436A (hr) |
PT (1) | PT1305307E (hr) |
SK (1) | SK286701B6 (hr) |
TR (1) | TR200401488T4 (hr) |
UA (1) | UA73995C2 (hr) |
WO (1) | WO2002008223A1 (hr) |
ZA (1) | ZA200300287B (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004291297B2 (en) | 2003-11-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Novel piperidine-substituted indoles- or heteroderivatives thereof |
TWI391387B (zh) * | 2004-05-12 | 2013-04-01 | Eisai R&D Man Co Ltd | 具有哌啶環之吲哚衍生物 |
WO2006117314A2 (en) | 2005-04-30 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Novel piperidin- substituted indoles and their use as ccr-3 modulators |
CA2667547C (en) | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
CN101486654B (zh) * | 2009-03-04 | 2012-10-10 | 西安近代化学研究所 | 2-甲基-3-硝基苯乙酸合成方法 |
CN110041318B (zh) * | 2018-01-17 | 2022-07-29 | 中国科学院上海药物研究所 | 一类多巴胺d5受体激动剂及其制备和应用 |
CN110498789B (zh) * | 2018-05-17 | 2022-04-05 | 上海医药工业研究院 | 芳烷哌啶类衍生物及其在多靶点抗抑郁症中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2322470A1 (de) * | 1973-05-04 | 1974-11-21 | Boehringer Sohn Ingelheim | Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung |
AT332401B (de) * | 1973-11-26 | 1976-09-27 | Roussel Uclaf | Verfahren zur herstellung von neuen (4'-(3''-indolyl)-piperidino)-alkylarylketonderivaten |
US4997841A (en) * | 1987-08-13 | 1991-03-05 | Glaxo Group Limited | Indole derivatives |
GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
CA2141810A1 (en) * | 1992-08-05 | 1994-02-17 | Ian A. Cliffe | Amide derivatives |
DK0695301T3 (da) * | 1993-04-22 | 1996-12-09 | Pfizer Ltd | Indolderivater som 5-HT1-lignende agonister til anvendelse ved migræne |
ES2063700B1 (es) * | 1993-04-28 | 1995-07-16 | Vita Invest Sa | Agente activo sobre el sistema nervioso central, proceso para su preparacion y composiciones farmaceuticas que lo contengan. |
US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
-
2001
- 2001-07-17 MX MXPA02012927A patent/MXPA02012927A/es active IP Right Grant
- 2001-07-17 DE DE60103162T patent/DE60103162T2/de not_active Expired - Fee Related
- 2001-07-17 IL IL15360501A patent/IL153605A0/xx unknown
- 2001-07-17 CZ CZ20030196A patent/CZ301114B6/cs not_active IP Right Cessation
- 2001-07-17 PT PT01960182T patent/PT1305307E/pt unknown
- 2001-07-17 NZ NZ523436A patent/NZ523436A/en unknown
- 2001-07-17 AT AT01960182T patent/ATE266024T1/de not_active IP Right Cessation
- 2001-07-17 KR KR1020037000850A patent/KR100851793B1/ko not_active IP Right Cessation
- 2001-07-17 HU HU0302820A patent/HUP0302820A3/hu unknown
- 2001-07-17 AU AU2001281738A patent/AU2001281738B2/en not_active Ceased
- 2001-07-17 EA EA200300179A patent/EA004749B1/ru not_active IP Right Cessation
- 2001-07-17 WO PCT/DK2001/000507 patent/WO2002008223A1/en active IP Right Grant
- 2001-07-17 EP EP01960182A patent/EP1305307B1/en not_active Expired - Lifetime
- 2001-07-17 BR BR0112998-8A patent/BR0112998A/pt not_active IP Right Cessation
- 2001-07-17 SK SK203-2003A patent/SK286701B6/sk not_active IP Right Cessation
- 2001-07-17 TR TR2004/01488T patent/TR200401488T4/xx unknown
- 2001-07-17 AU AU8173801A patent/AU8173801A/xx active Pending
- 2001-07-17 CA CA002416212A patent/CA2416212C/en not_active Expired - Fee Related
- 2001-07-17 CN CNB018151078A patent/CN1264838C/zh not_active Expired - Fee Related
- 2001-07-17 ES ES01960182T patent/ES2219554T3/es not_active Expired - Lifetime
- 2001-07-17 JP JP2002514129A patent/JP2004504396A/ja active Pending
- 2001-07-17 UA UA2003010167A patent/UA73995C2/uk unknown
- 2001-07-20 AR ARP010103457A patent/AR029858A1/es unknown
-
2002
- 2002-12-23 IS IS6663A patent/IS2172B/is unknown
- 2002-12-24 IL IL153605A patent/IL153605A/en not_active IP Right Cessation
-
2003
- 2003-01-09 HR HR20030015A patent/HRP20030015A2/hr not_active Application Discontinuation
- 2003-01-10 ZA ZA200300287A patent/ZA200300287B/en unknown
- 2003-01-10 NO NO20030127A patent/NO323799B1/no not_active IP Right Cessation
- 2003-01-17 US US10/347,574 patent/US6743809B2/en not_active Expired - Fee Related
- 2003-02-05 BG BG107528A patent/BG107528A/bg unknown
-
2004
- 2004-04-15 HK HK04102653A patent/HK1059782A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7105543B2 (en) | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | |
US7276508B2 (en) | Indole derivatives useful for the treatment of CNS disorders | |
HRP20030015A2 (en) | Indole derivatives useful for the treatment of cns disorders | |
AU2001279611A1 (en) | 4-, 5-, 6- and 7-indole derivatives useful for the treatment of CNS disorders | |
AU2001281738A1 (en) | Indole derivatives useful for the treatment of cns disorders | |
EP1468996B1 (en) | Indole derivatives for the treatment of CNS disorders | |
PL203538B1 (pl) | Podstawiona pochodna indolu i jej zastosowanie oraz kompozycja farmaceutyczna | |
IL153234A (en) | Indole derivatives and pharmaceutical compositions containing them for the treatment of cns disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040701 Year of fee payment: 4 |
|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn |